NewsRoom Articles - BioMedWire (BMW)

MondayApr 20, 2026 9:00 am

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector historically defined by long timelines and uncertain outcomes. As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being reinforced by fair-value accounting under U.S. GAAP, which allows life sciences companies to reflect clinical progress, probability of success and commercialization timing as measurable balance sheet value. Leading companies, such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), are keenly aware of this evolution and…

FridayApr 17, 2026 12:10 pm

Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies. Soligenix announced that the European Commission granted orphan drug designation to SGX945 for the treatment of Behçet’s disease. SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators. Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug…

FridayApr 17, 2026 10:50 am

Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built

Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug…

FridayApr 17, 2026 10:00 am

Americans are Supplementing Healthcare Visits with AI, Gallup Survey Finds

A survey that was conducted toward the end of last year by Gallup and West Health found that a sizeable number of Americans are using AI to supplement their interactions with healthcare providers. However, the specifics of how people used these digital tools varied based on age groups, income level and motivations. The survey was carried out from October 27 to December 22 in 2025. A total of 5,500 adults participated in the poll that was designed to be nationally representative. Among those who had used AI in the last 30 days, 59% said they used AI tools to conduct research on their own prior to visiting their doctor.…

ThursdayApr 16, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

Soligenix reports clinical update centered on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin. The interim update highlighted that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting. In addition, the company reported positive results from a study evaluating HyBryte(TM) against Valchlor(R), an existing treatment option for cutaneous T-cell lymphoma. Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is demonstrating that momentum as it provides both an encouraging clinical update from its…

ThursdayApr 16, 2026 10:00 am

New AI Tool Could Boost the Early Detection of Lung Cancer

Lung cancer is the leading cause of cancer-linked fatalities among men and women, and survival beyond five years post-diagnosis is minimal. This is largely because most cases are detected when they are already advanced. Scientists are therefore searching for ways to boost early detection so that treatment outcomes can improve and survival can increase. A new study seems to have found a way to use AI to improve the early detection of this disease. This tool could be especially helpful in flagging lung cancer when tumors are still small and are harder to detect using the existing diagnostic tools. These existing tools, such as CT scans, have…

ThursdayApr 16, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech Through AI-Robotics Pivot, Unlocking New Value in GMP Automation

Oncotelic Therapeutics has recently entered a strategic partnership with TechForce Robotics to commercialize a PDAOAI-enhanced, GMP-compliant robotics platform The collaboration integrates AI-driven compliance systems with advanced robotics for pharmaceutical manufacturing automation This pivot underscores a broader strategy: extending Oncotelic’s AI capabilities beyond therapeutics into scalable, high-value industrial applications Oncotelic Therapeutics (OTCQB: OTLC) is signaling a significant strategic evolution, moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced…

WednesdayApr 15, 2026 9:45 am

Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients

For a long time, proton therapy wasn’t available for many cancer patients due to the footprint of traditional proton therapy equipment and the high costs associated with it. However, the size and cost of this equipment is shrinking, opening it up as a more viable treatment option for cancer patients. Liora Technologies, a subsidiary of LIXTE Biotechnology Holdings, Inc., is poised to offer compact, precise, and accessible proton therapy through the innovative Linac for Image Guided Hadron Therapy (“LiGHT”) System. Proton therapy is a specialized cancer treatment that uses precision-guided radiation beams to target and destroy tumors while limiting harm…

WednesdayApr 15, 2026 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Gains Analytical Validation as Pipeline Progress Drives Forward Outlook

A recent Zacks Small-Cap Research report outlines a number of key milestones that position Soligenix for a potentially eventful period ahead. One of the most notable elements highlighted in the analysis is the strength of the interim data trends observed thus far in the FLASH2 study. Beyond the phase 3 program, the report highlights additional clinical and scientific developments that contribute to the depth of Soligenix’s pipeline. Independent research coverage can play a meaningful role in shaping how emerging biotechnology companies are evaluated, particularly when it brings together clinical progress, financial positioning and forward-looking milestones into a cohesive outlook. A…

TuesdayApr 14, 2026 10:00 am

Preclinical Study Reveals Promising Treatment for Glioblastoma

Glioblastoma is a deadly type of brain cancer which progresses rapidly and kills victims within months. For nearly two decades, no significant progress has been made in developing an effective treatment against this malignancy. Now, a new preclinical study using animal models has unveiled a potential breakthrough that could eliminate these tumors. The study, whose findings were published in the journal Nature, was conducted by scientists at the startup Trogenix. The team is made up of scientists at the Cancer Institute at University College London, the Royal Infirmary at Edinburgh, and the University of Edinburgh. The team developed SSEs technology (Synthetic Super-Enhancers) that entails using a viral vector to carry genetic instructions into glioblastoma tumors. The genetic instructions…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built

Americans are Supplementing Healthcare Visits with AI, Gallup Survey Finds

Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

New AI Tool Could Boost the Early Detection of Lung Cancer

Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech Through AI-Robotics Pivot, Unlocking New Value in GMP Automation

Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients

Soligenix Inc. (NASDAQ: SNGX) Gains Analytical Validation as Pipeline Progress Drives Forward Outlook

Preclinical Study Reveals Promising Treatment for Glioblastoma

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search